Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic

ImCheck Therapeutics an @Ipsen company designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.